| CBIT+TMS R33 Phase (NCT06678737) | University of Minnesota | 2025-02-27 |
| A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) (NCT06881251) | Janssen Research & Development, LLC | 2025-02-26 |
| Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC (NCT06855212) | H. Lee Moffitt Cancer Center and Research Institute | 2025-02-26 |
| A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee (NCT06884865) | Pacira Pharmaceuticals, Inc | 2025-02-26 |
| A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC (NCT06745323) | Amgen | 2025-02-26 |
| FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (NCT06909825) | Fusion Pharmaceuticals Inc. | 2025-02-26 |
| Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer (NCT06763029) | Fudan University | 2025-02-26 |
| A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers (NCT06805617) | Glenn J. Hanna | 2025-02-26 |
| Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) (NCT06686394) | Merck Sharp & Dohme LLC | 2025-02-26 |
| A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer (NCT06778031) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-02-26 |
| Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer (NCT05093231) | Cambridge University Hospitals NHS Foundation Trust | 2025-02-26 |
| A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors (NCT06848699) | Shanghai Henlius Biotech | 2025-02-25 |
| Modulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains (NCT06795451) | University of Cincinnati | 2025-02-25 |
| ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis (NCT06680661) | Leland Metheny | 2025-02-25 |
| The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC) (NCT06789757) | Inova Health Care Services | 2025-02-25 |
| Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma (NCT06376669) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2025-02-25 |
| Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer (NCT07084610) | Hospital das Clínicas de Ribeirão Preto | 2025-02-25 |
| A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder (NCT06673368) | Neurocentria, Inc. | 2025-02-25 |
| Intranasal Insulin for Treatment of Alcohol Use Disorder (NCT05988632) | Brown University | 2025-02-25 |
| Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Patients With Decompensated Hepatitis B Cirrhosis (NCT07413549) | Beijing Tuohua Weiye Biotechnology Co., Ltd. | 2025-02-25 |
| Convergent Mechanisms Underlying Reprometabolic Syndrome in Women (NCT06686537) | University of Colorado, Denver | 2025-02-25 |
| Analysis of the Hormonal Implant and Transdermal Estradiol Gel in Climacteric Women (NCT07754630) | Nutrindo Ideais Research Center | 2025-02-25 |
| Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder (NCT06592833) | Icahn School of Medicine at Mount Sinai | 2025-02-25 |
| IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) (NCT06849986) | Fudan University | 2025-02-25 |
| Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC (NCT06811844) | The First Affiliated Hospital of Xiamen University | 2025-02-25 |
| A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy (NCT06816251) | Shandong Suncadia Medicine Co., Ltd. | 2025-02-25 |
| Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis (NCT06519591) | Ruijin Hospital | 2025-02-25 |
| Evaluating Pediatric Ivermectin in Children Under 15 kg (EPIC-15) (NCT06404333) | University of Oxford | 2025-02-25 |
| Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC (NCT06860386) | H. Lee Moffitt Cancer Center and Research Institute | 2025-02-25 |
| A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML (NCT06563804) | Servier Bio-Innovation LLC | 2025-02-25 |
| An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia (NCT06712823) | Crinetics Pharmaceuticals Inc. | 2025-02-25 |
| Phase IIa Study for IPG11406 in Patients With Lupus Nephritis (NCT06717815) | Nanjing Immunophage Biotech Co., Ltd | 2025-02-25 |
| Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant (NCT06938867) | SNIPR Biome Aps. | 2025-02-25 |
| A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use (NCT06804603) | Vanda Pharmaceuticals | 2025-02-25 |
| Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC (NCT06838208) | Anhui Provincial Cancer Hospital | 2025-02-25 |
| Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants (NCT06737042) | Gan and Lee Pharmaceuticals, USA | 2025-02-24 |
| A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer (NCT06838546) | Tasly Biopharmaceuticals Co., Ltd. | 2025-02-24 |
| Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults (NCT06728553) | Manistee Therapeutics | 2025-02-24 |
| A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors (NCT06741644) | CStone Pharmaceuticals | 2025-02-24 |
| EFFICACY OF COLCHICINE IN IMPROVING CLINICAL OUTCOMES IN PATIENTS WITH MILD TO MODERATE COVID-19 PNEUMONIA IN LAHORE: A RANDOMIZED CONTROL TRIAL (NCT06847204) | Zaeema Kanwal | 2025-02-24 |
| A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy (NCT06797297) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-02-24 |
| A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults (NCT06680128) | SK Bioscience Co., Ltd. | 2025-02-24 |
| An Exploratory Study to Evaluate the Efficacy and Safety of FCN-159 in Patients With Brain Arteriovenous Malformations (NCT06913725) | Xuanwu Hospital, Beijing | 2025-02-24 |
| An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis (NCT06617793) | Novartis Pharmaceuticals | 2025-02-24 |
| Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer (NCT06369259) | M.D. Anderson Cancer Center | 2025-02-24 |
| Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer (NCT06833502) | H. Lee Moffitt Cancer Center and Research Institute | 2025-02-24 |
| Personalized Antisense Oligonucleotide for a Single Participant With MAPK8IP3 Neurodevelopmental Disorder With or Without Variable Brain Abnormalities (NEDBA) (NCT07197294) | n-Lorem Foundation | 2025-02-24 |
| Phase II Study of JT002 in the Treatment of Seasonal Allergic Rhinitis in Adults (NCT06861101) | Shanghai JunTop Biosciences Co., LTD | 2025-02-24 |
| Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma (NCT07326995) | Anhui Palo Alto Pharmaceuticals, Inc. | 2025-02-24 |
| A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer (NCT06503614) | John Sfakianos | 2025-02-24 |
| Intra-lesional Tumor Boost for Bulky Cervical Cancer (NCT07435376) | Seoul National University Bundang Hospital | 2025-02-23 |
| Effect of Rutin on Inflammation Pathways in Ulcerative Colitis Patients (NCT07370220) | Benha University | 2025-02-22 |
| Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC (NCT06856278) | Zhejiang Provincial People's Hospital | 2025-02-22 |
| A Double-blind Non Inferiority Clinical Trial to Compare the Nephroprotection of Cilastatn Versus Thiosulfate in Patients Undergoing Debulking Surgery With Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Cisplatin. (NCT07229040) | Hospital General Universitario Gregorio Marañon | 2025-02-21 |
| Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN (NCT06797518) | Novartis Pharmaceuticals | 2025-02-21 |
| Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC (NCT06623656) | Weill Medical College of Cornell University | 2025-02-21 |
| A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study (NCT06630091) | M.D. Anderson Cancer Center | 2025-02-21 |
| Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma. (NCT06854510) | Sun Yat-sen University | 2025-02-21 |
| Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE). (NCT06601127) | Tianjin Institute of Pharmaceutical Research Co., Ltd | 2025-02-21 |
| A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease (NCT06826612) | Hoffmann-La Roche | 2025-02-21 |
| Retinoblastoma Phase II Expanded Access Clinical Trial (NCT06679634) | Targeted Therapy Technologies, LLC | 2025-02-21 |
| Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain (NCT06848348) | Dogwood Therapeutics Inc. | 2025-02-21 |
| Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma (NCT06558604) | The Lymphoma Academic Research Organisation | 2025-02-21 |
| Evaluating Mechanically Engineered Stem Cell Exosomes for Treating Endometrial Injury: A Clinical Study (NCT06896747) | Tang-Du Hospital | 2025-02-21 |
| Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis (NCT05309616) | Yale University | 2025-02-20 |
| Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC) (NCT06796803) | Shanghai Zhongshan Hospital | 2025-02-20 |
| Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) (NCT06390956) | University of Utah | 2025-02-20 |
| CMTS4520-Assisted Washed Microbiota Transplantation for Chronic Constipation in Adults (NCT06832176) | The Second Hospital of Nanjing Medical University | 2025-02-20 |
| Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19. (NCT06869473) | Gruppo Oncologico del Nord-Ovest | 2025-02-20 |
| Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance. (NCT07284316) | Instituto Mexicano del Seguro Social | 2025-02-20 |
| A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors (NCT06769152) | Shanghai Henlius Biotech | 2025-02-20 |
| Psyllium in Pediatric IBS (NCT06639984) | Dr Bruno Chumpitazi, M.D. | 2025-02-20 |
| A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma (NCT06843434) | Memorial Sloan Kettering Cancer Center | 2025-02-20 |
| Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer (NCT06250036) | Royal Marsden NHS Foundation Trust | 2025-02-20 |
| Clinical Study of ASN-3186 in Patients with Advanced Solid Tumors (NCT06787950) | Jiangsu Yahong Meditech Co., Ltd aka Asieris | 2025-02-20 |
| Oral Metformin for Treating Melasma in Latin American Women (NCT06845540) | University of Puerto Rico | 2025-02-20 |
| SNV4818 in Participants With Advanced Solid Tumors (NCT06736704) | Pikavation Therapeutics, Inc. | 2025-02-20 |
| Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer (NCT06702618) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-02-20 |
| Impact of LLL and Aerobic Exercise on Peripheral Arterial Outcomes in Patients With Type 2 Diabetes (NCT06827171) | Nouran Hesham Slama Younis | 2025-02-20 |
| CMTS4520-Assisted Washed Microbiota Transplantation for Chronic Diarrhoea in Adults (NCT06839599) | The Second Hospital of Nanjing Medical University | 2025-02-20 |
| Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition (NCT06605586) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2025-02-20 |
| A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis（ KOA） (NCT06741098) | Nuwacell Biotechnologies Co., Ltd. | 2025-02-20 |
| CMTS4520 for Chronic Diarrhoea in Adults (NCT06839586) | The Second Hospital of Nanjing Medical University | 2025-02-20 |
| Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer. (NCT06670911) | Instituto Nacional de Cancer, Brazil | 2025-02-20 |
| A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC (NCT06672068) | TYK Medicines, Inc | 2025-02-20 |
| The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer (NCT05798845) | Shanghai Chest Hospital | 2025-02-20 |
| ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC (NCT07157969) | Peking Union Medical College Hospital | 2025-02-19 |
| Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST) (NCT06902311) | UNC Lineberger Comprehensive Cancer Center | 2025-02-19 |
| Hypertonic Lactate After Cardiac Arrest (NCT05004610) | Erasme University Hospital | 2025-02-19 |
| A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region. (NCT06272812) | International AIDS Vaccine Initiative | 2025-02-19 |
| A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) (NCT06980805) | Immunovant Sciences GmbH | 2025-02-19 |
| A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma (NCT06843967) | Memorial Sloan Kettering Cancer Center | 2025-02-19 |
| DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY (NCT06749210) | Ohio State University Comprehensive Cancer Center | 2025-02-19 |
| A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease. (NCT06769984) | Sinocelltech Ltd. | 2025-02-19 |
| Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors (NCT06358677) | University of Utah | 2025-02-19 |
| A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors (NCT06703177) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-02-18 |
| A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone (NCT06862791) | AstraZeneca | 2025-02-18 |
| Treatment of Deficient Interdental Papilla Using Albumin-platelets Rich Fibrin (NCT06842277) | Cairo University | 2025-02-18 |
| A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer (NCT06567782) | GlaxoSmithKline | 2025-02-18 |
| Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. (NCT06514534) | Novartis Pharmaceuticals | 2025-02-18 |